Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Pediatrics
Published in: European Journal of Pediatrics 8/2019

Open Access 01-08-2019 | Patent Ductus Arteriosus | Original Article

Efficacy and safety of systemic hydrocortisone for the prevention of bronchopulmonary dysplasia in preterm infants: a systematic review and meta-analysis

Authors: Ian Paul Morris, Nitin Goel, Mallinath Chakraborty

Published in: European Journal of Pediatrics | Issue 8/2019

Login to get access

Abstract

Early lung inflammation has been implicated in the pathogenesis of bronchopulmonary dysplasia (BPD). We aimed to establish the efficacy and safety of systemic hydrocortisone for the prevention of BPD. A systematic review and meta-analysis were undertaken, with a detailed electronic literature search. Trials involving preterm infants were included if they were randomised to receive systemic hydrocortisone or a placebo. The primary outcome was the composite of survival without BPD at 36-week postmenstrual age (PMA). Results are presented as relative risk (RR) or risk difference (RD) with 95% confidence intervals (CIs), along with numbers needed to treat (NNT) or harm (NNH). After filtering, 12 studies using early (within 1 week of birth) and two using late hydrocortisone were identified. Early systemic hydrocortisone significantly increased the chances of survival without BPD (RR 1.13, 95% CI [1.01, 1.26], NNT 18), and survival without moderate-to-severe neurodevelopmental impairment (1.13 [1.02, 1.26], NNT 14). Infants who received hydrocortisone had a higher risk of intestinal perforation (1.69 [1.07, 2.68], NNH 30), primarily with concurrent treatment for patent ductus arteriosus.
Conclusion: Early systemic hydrocortisone is a modestly effective therapy for the prevention of BPD in preterm infants, although some safety concerns remain. No conclusions could be drawn for late hydrocortisone due to the paucity of studies.
What is Known:
• Preterm infants are at high risk of developing bronchopulmonary dysplasia (BPD) and early lung inflammation plays a significant role in its pathogenesis.
• Both early and late systemic dexamethasone seems to reduce the incidence of BPD, but its use is associated with serious neurodevelopmental impairment at follow-up.
What is New:
• Early systemic hydrocortisone significantly improved survival without BPD at 36 weeks and survival without moderate to severe neurodevelopmental impairment on follow up.
• Incidence of gastrointestinal perforation associated with concurrent treatment for PDA was significantly higher, although early systemic hydrocortisone reduced the need for treatment of PDAs.
Appendix
Available only for authorised users
Literature
1.
2.
Vom Hove M et al (2014) Pulmonary outcome in former preterm, very low birth weight children with bronchopulmonary dysplasia: a case-control follow-up at school age. J Pediatr 164(1):40–45 e4CrossRefPubMed
3.
Bolton CE, Bush A, Hurst JR, Kotecha S, McGarvey L (2015) Lung consequences in adults born prematurely. Thorax 70(6):574–580CrossRefPubMed
4.
Anderson PJ, Doyle LW (2006) Neurodevelopmental outcome of bronchopulmonary dysplasia. Semin Perinatol 30(4):227–232CrossRefPubMed
5.
Chakraborty M, McGreal EP, Kotecha S (2010) Acute lung injury in preterm newborn infants: mechanisms and management. Paediatr Respir Rev 11(3):162–70; quiz 170CrossRefPubMed
6.
Doyle LW, Ehrenkranz RA, Halliday HL (2014) Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 5:CD001146
7.
Doyle LW, Ehrenkranz RA, Halliday HL (2014) Late (> 7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 5:CD001145
8.
9.
Kersbergen KJ, de Vries LS, van Kooij BJM, Išgum I, Rademaker KJ, van Bel F, Hüppi PS, Dubois J, Groenendaal F, Benders MJNL (2013) Hydrocortisone treatment for bronchopulmonary dysplasia and brain volumes in preterm infants. J Pediatr 163(3):666–71 e1CrossRefPubMed
10.
Rademaker KJ, de Vries LS, Uiterwaal CSPM, Groenendaal F, Grobbee DE, van Bel F (2008) Postnatal hydrocortisone treatment for chronic lung disease in the preterm newborn and long-term neurodevelopmental follow-up. Arch Dis Child Fetal Neonatal Ed 93(1):F58–F63CrossRefPubMed
11.
Yamasaki C, Uchiyama A, Nakanishi H, Masumoto K, Aoyagi H, Washio Y, Totsu S, Imai K, Kusuda S (2012) Hydrocortisone and long-term outcomes in very-low-birthweight infants. Pediatr Int 54(4):465–470CrossRefPubMed
12.
Doyle LW, Ehrenkranz RA, Halliday HL (2010) Postnatal hydrocortisone for preventing or treating bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology 98(2):111–117CrossRefPubMed
13.
Jobe AH, Bancalari E (2001) Bronchopulmonary dysplasia. Am J Respir Crit Care Med 163(7):1723–1729CrossRef
14.
Papile LA, Burstein J, Burstein R, Koffler H (1978) Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr 92(4):529–534CrossRef
15.
Walsh MC, Kliegman RM (1986) Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin N Am 33(1):179–201CrossRef
16.
Wan X et al (2014) Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 14:135CrossRefPubMedPubMedCentral
17.
Newcombe RG (1998) Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 17(8):873–890CrossRefPubMed
18.
Baden M et al (1972) A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome. Pediatrics 50(4):526–534PubMed
19.
20.
Baud O, Maury L, Lebail F, Ramful D, el Moussawi F, Nicaise C, Zupan-Simunek V, Coursol A, Beuchée A, Bolot P, Andrini P, Mohamed D, Alberti C (2016) Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial. Lancet 387(10030):1827–1836CrossRefPubMed
21.
Biswas S et al (2003) Pulmonary effects of triiodothyronine (T3) and hydrocortisone (HC) supplementation in preterm infants less than 30 weeks gestation: results of the THORN trial--thyroid hormone replacement in neonates. Pediatr Res 53(1):48–56PubMed
22.
Bonsante F, Latorre G, Iacobelli S, Forziati V, Laforgia N, Esposito L, Mautone A (2007) Early low-dose hydrocortisone in very preterm infants: a randomized, placebo-controlled trial. Neonatology 91(4):217–221CrossRefPubMed
23.
Bourchier D, Weston PJ (1997) Randomised trial of dopamine compared with hydrocortisone for the treatment of hypotensive very low birthweight infants. Arch Dis Child Fetal Neonatal Ed 76(3):F174–F178CrossRefPubMedPubMedCentral
24.
Efird MM, Heerens AT, Gordon PV, Bose CL, Young DA (2005) A randomized-controlled trial of prophylactic hydrocortisone supplementation for the prevention of hypotension in extremely low birth weight infants. J Perinatol 25(2):119–124CrossRefPubMed
25.
Hochwald O, Palegra G, Osiovich H (2014) Adding hydrocortisone as 1st line of inotropic treatment for hypotension in very low birth weight infants. Indian J Pediatr 81(8):808–810CrossRefPubMed
26.
Ng PC, Lee CH, Bnur FL, Chan IH, Lee AW, Wong E, Chan HB, Lam CW, Lee BS, Fok TF (2006) A double-blind, randomized, controlled study of a “stress dose” of hydrocortisone for rescue treatment of refractory hypotension in preterm infants. Pediatrics 117(2):367–375CrossRefPubMed
27.
Peltoniemi O, Kari MA, Heinonen K, Saarela T, Nikolajev K, Andersson S, Voutilainen R, Hallman M (2005) Pretreatment cortisol values may predict responses to hydrocortisone administration for the prevention of bronchopulmonary dysplasia in high-risk infants. J Pediatr 146(5):632–637CrossRefPubMed
28.
Watterberg KL, Gerdes JS, Gifford KL, Lin HM (1999) Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics 104(6):1258–1263CrossRefPubMed
29.
Watterberg KL, Gerdes JS, Cole CH, Aucott SW, Thilo EH, Mammel MC, Couser RJ, Garland JS, Rozycki HJ, Leach CL, Backstrom C, Shaffer ML (2004) Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics 114(6):1649–1657CrossRefPubMed
30.
Dobryanskyy D et al (2012) Clinical effectiveness of early administration of caffeine and low-dose hydrocortisone to preterm newborns with a high risk of BPD development. In: 4th Congress of the European Academy of Paediatric Societies. Archives of disease in childhood. Turkey, Istanbul, p A119
31.
Baud O, Trousson C, Biran V, Leroy E, Mohamed D, Alberti C, for the PREMILOC Trial Group (2017) Association between early low-dose hydrocortisone therapy in extremely preterm neonates and neurodevelopmental outcomes at 2 years of age. JAMA 317(13):1329–1337CrossRefPubMed
32.
Fitzhardinge PM et al (1974) Sequelae of early steroid administration to the newborn infant. Pediatrics 53(6):877–883PubMed
33.
Peltoniemi OM, Lano A, Puosi R, Yliherva A, Bonsante F, Kari MA, Hallman M, Neonatal Hydrocortisone Working Group (2009) Trial of early neonatal hydrocortisone: two-year follow-up. Neonatology 95(3):240–247CrossRefPubMed
34.
Peltoniemi OM, Lano A, Yliherva A, Kari MA, Hallman M, for The Neonatal Hydrocortisone Working Group (2016) Randomised trial of early neonatal hydrocortisone demonstrates potential undesired effects on neurodevelopment at preschool age. Acta Paediatr 105(2):159–164CrossRefPubMed
35.
Watterberg KL, Shaffer ML, Mishefske MJ, Leach CL, Mammel MC, Couser RJ, Abbasi S, Cole CH, Aucott SW, Thilo EH, Rozycki HJ, Lacy CB (2007) Growth and neurodevelopmental outcomes after early low-dose hydrocortisone treatment in extremely low birth weight infants. Pediatrics 120(1):40–48CrossRefPubMed
36.
Kazzi NJ, Brans YW, Poland RL (1990) Dexamethasone effects on the hospital course of infants with bronchopulmonary dysplasia who are dependent on artificial ventilation. Pediatrics 86(5):722–727PubMed
37.
Parikh NA, Kennedy KA, Lasky RE, McDavid GE, Tyson JE (2013) Pilot randomized trial of hydrocortisone in ventilator-dependent extremely preterm infants: effects on regional brain volumes. J Pediatr 162(4):685–690.e1CrossRefPubMed
38.
Onland W, Cools F, Kroon A, Rademaker K, Merkus MP, Dijk PH, van Straaten HL, te Pas AB, Mohns T, Bruneel E, van Heijst AF, Kramer BW, Debeer A, Zonnenberg I, Marechal Y, Blom H, Plaskie K, Offringa M, van Kaam AH, for the STOP-BPD Study Group (2019) Effect of hydrocortisone therapy initiated 7 to 14 days after birth on mortality or bronchopulmonary dysplasia among very preterm infants receiving mechanical ventilation: a randomized clinical trial. JAMA 321(4):354–363CrossRefPubMedPubMedCentral
39.
Parikh NA, Kennedy KA, Lasky RE, Tyson JE (2015) Neurodevelopmental outcomes of extremely preterm infants randomized to stress dose hydrocortisone. PLoS One 10(9):e0137051CrossRefPubMedPubMedCentral
40.
Stark AR, Carlo WA, Tyson JE, Papile LA, Wright LL, Shankaran S, Donovan EF, Oh W, Bauer CR, Saha S, Poole WK, Stoll BJ, Fanaroff AA, Ehrenkranz RA, Korones SB, Stevenson DK (2001) Adverse effects of early dexamethasone treatment in extremely-low-birth-weight infants. National Institute of Child Health and Human Development neonatal research network. N Engl J Med 344(2):95–101CrossRefPubMed
41.
Ngo S, Profit J, Gould JB, Lee HC (2017) Trends in patent ductus arteriosus diagnosis and management for very low birth weight infants. Pediatrics 139(4):e20162390CrossRefPubMedPubMedCentral
42.
Gupta S et al (2012) Postnatal corticosteroids for prevention and treatment of chronic lung disease in the preterm newborn. Int J Pediatr 2012:315642CrossRefPubMed
43.
Watterberg KL, Shaffer ML, Garland JS, Thilo EH, Mammel MC, Couser RJ, Aucott SW, Leach CL, Cole CH, Gerdes JS, Rozycki HJ, Backstrom C (2005) Effect of dose on response to adrenocorticotropin in extremely low birth weight infants. J Clin Endocrinol Metab 90(12):6380–6385CrossRefPubMed
44.
Stone DL, Rosopa PJ (2017) The advantages and limitations of using meta-analysis in human resource management research. Hum Resour Manag Rev 27(1):1–7CrossRef
45.
Cardoso FGC, Formiga CKMR, Bizinotto T, Tessler RB, Rosa Neto F (2017) Concurrent validity of the BRUNET-LÉZINE scale with the BAYLEY scale for assessment of the development of preterm infants up to two years. Revista Paulista de Pediatria 35(2):144–150CrossRefPubMedPubMedCentral
Metadata
Title
Efficacy and safety of systemic hydrocortisone for the prevention of bronchopulmonary dysplasia in preterm infants: a systematic review and meta-analysis
Authors
Ian Paul Morris
Nitin Goel
Mallinath Chakraborty
Publication date
01-08-2019
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Pediatrics / Issue 8/2019
Print ISSN: 0340-6199
Electronic ISSN: 1432-1076
DOI
https://doi.org/10.1007/s00431-019-03398-5

Other articles of this Issue 8/2019

European Journal of Pediatrics 8/2019 Go to the issue

Original Article

Benefits of medical clowning in the treatment of young children with autism spectrum disorder

Original Article

Oral vitamin A supplementation in very low birth weight neonates: a randomized controlled trial

Original Article

Estimation of the proportion of metabolic syndrome-free subjects on high cardiometabolic risk using two continuous cardiometabolic risk scores: a cross-sectional study in 16- to 20-year-old individuals

Original Article

Ten-year trend in prevalence and outcome of Down syndrome with congenital heart disease in a middle-income country

Short Communication

A new simple formula built on the American Academy of Pediatrics criteria for the screening of hypertension in overweight/obese children

Original Article

Endotracheal intubation skills of pediatricians versus anesthetists in neonates and children